Category: FDA
-
Key Insights from FDA’s Psychedelic Drug Hearing
On September 14, 2026, the FDA hosted a public hearing on psychedelic drug therapy considerations, attracting 80 speakers who debated training, safety, access, and data standards. Consensus emerged on the need for interdisciplinary care and robust safety measures post-treatment. The hearing emphasized that effective psychedelic care relies on integrated systems rather than isolated approaches.